Compound ID | 1820
Class: Beta-lactamase inhibitor (diazabicyclooctane [DBO])
Spectrum of activity: | Gram-negative |
Details of activity: | Inhibits PBP2 and is unaffected by β-lactamase mediated resistance. Active against Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii |
Description: | Synthetic compound. Inhibitor of serine Beta-Lactamases |
Institute where first reported: | Entasis Therapeutics |
Year first mentioned: | 2021 |
Highest developmental phase: | Preclinical |
Development status: | Active (as of 2022) |
Chemical structure(s): | |||||||||||
|
|
External links: | |
PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/155920149 |
Guide to Pharmacology: | ETX0462 |
Citation: | https://www.nature.com/articles/s41586-021-03899-0 |